AIMT News and Press, Aimmune Therapeutics Inc. From 12/13/19

Does the management have a determination to continue to develop products or processes that will further increase total sales potentials when the growth potentials of currently attractive product lines have largely been exploited? - Philip Fisher If you've been following my blog , you'...

Arrowhead Pharmaceuticals (NASDAQ: ARWR ) initiated with Market Perform rating at Oppenheimer. More news on: Arrowhead Pharmaceuticals, Inc., Exact Sciences Corporation, Ionis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

In 1992, Congress passed the Prescription Drug User Fee Act (PDUFA) allowing the U.S. Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the drug review and approval process. To promote getting novel medicines to patients expeditiously, the act requires the FDA to...

Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in three upcoming investor conferences in November and December: Event...

It might be hard to believe, but in just seven weeks we'll be saying our goodbyes to 2019. Although investors have endured a couple of short-lived rough patches, it's been an exceptionally strong year for the stock market. The broad-based  S&P 500  is up 23%, the iconic  Dow J...

—New Data at ACAAI Reinforce the Need for Treatments to Reduce the Fear of Accidental Exposure to Peanut and Improve Emotional Well-Being for Adult Patients and Caregivers— Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for pot...

— Findings Suggest that a Strong Clinical History, in Combination with Evidence of Peanut Sensitization, is the Optimal Approach to Identify Highly Sensitive Peanut-Allergic Patients — Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatm...

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today revealed that the logistical needs for implementing oral immunotherapy (OIT) for food allergies, such as peanut allergy, into clinical practice is...

—Despite Differing Study Designs, Patient Criteria and Geographies of the Two Landmark Clinical Trials, Results Were Consistent for AR101-Treated Patients Compared to Placebo— Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for ...